Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- Change in Blood transfusion frequency
研究概览
简要总结
The goal of this clinical trial is to find out the efficacy of combined Hydroxyurea and thalidomide transfusion dependent thalassemia patients. The main objectives are to compare the level of Hb, Transfusion interval, serum ferritin level before & after treatment between single and combination of thalidomide and HU.
Researcher will compare the effectiveness of combined hydroxyurea and thalidomide and hydroxyurea and thalidomide alone. Participants will be divided in three groups:
Group I: will take combination of HU and Thalidomide. Group II: Will take HU alone and Group III: Will take Thalidomide alone and outcome will be recorded.
详细描述
Thalassemia is a monogenic hematological disorder caused as a result of defect in synthesis of globin chains of hemoglobin. It causes ineffective erythropoiesis & lysis of red blood cells due to relative excess of unaffected globin chain.
Annually about 50,000 children with a severe form of thalassemia (β-thalassemia major and HbE β-thalassemia) born globally among which 26,000 patients are regular blood transfusion dependent. About 70-75% patients are found in southeast asia & eastern mediterranean region.
Hematopoietic stem cell transplant (HSCT) is the only curative treatment option for homozygous thalassemia patients. Unfortunately its application is limited due to scarcity of HLA-matched donor, high cost , lack of specialized dedicated centers and risk of transplant related morbidity and mortality.
Regular blood transfusion is an essential life saving supportive care to maintain growth and development in children with severe β-thalassemia. However, Long term blood transfusion causes iron overload with cardiac, hepatic and endocrine coomplications , spread transfusion transmitted infections and formation of antibody. These limitations have compelled researchers to search for novel therapeutic modalities.
In recent years, induction of Fetal Hemoglobin (HbF) production pharmacologically is an promising treatment options for hemoglobinopathies. Different HbF inducing agents like Hydroxyurea (HU), Butyrate derivatives, Azacitidine, Decitabine, Tricostatin-A are shown to be effective in decreasing clinical severity and complications of TDT. HU induces a 2-9 fold increase in γ-globin gene and being used for decades in thalassemia treatment. But its utility is limited due to its mild and ill sustained therapeutic effect in HbF synthesis. Thalidomide, an immunomodulatory drug also shown to produce significant and persistent rise in Hb in few small studies and several case reports. It induces Gamma Globin gene expression by increasing reactive oxygen species-mediated p38 mitogen-activated protein kinase (MAPK) signaling and histone H4 acetylation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 3 Years 至 18 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed as transfusion dependent thalassemia
- •Age ranged from 3-18 years
- •Blood transfusion more than 1 year.
- •no bleeding disorder
排除标准
- •Active systemic co-morbidity,
- •Past personal or family history of thrombophilia,
- •Recent fracture or recent major surgery
- •Use of drugs that might affect Hb levels 15 days before enrollment
研究组 & 干预措施
Hydroxyurea
Hydroxyurea
干预措施: Hydroxy Urea (Drug)
Thalidomide
Patient getting Thalidomide
干预措施: Thalidomide (Drug)
Combination
combination of Thalidomide & Hydroxyurea
干预措施: Combinations (Drug)
结局指标
主要结局
Change in Blood transfusion frequency
时间窗: 12 weeks after treatment initiation
Change in Blood transfusion frequency after 3 month
Change in Hb Level
时间窗: 12 weeks after treatment initiation
Change in Hb gm/dl after 3 month
Change in HbF
时间窗: 12 weeks after treatment initiation
Change in Hb F after 3 month
次要结局
- Adverse effect(12 weeks from treatment initiation)
- Change in Biochemicals(12 weeks after treatment initiation)
研究者
MD ANWARUL KARIM
Professor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
